Evidence map›Paper›PMID 37213801›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2023

Italian Association of Hospital Cardiologists practical guidance for sodium-glucose cotransporter 2 inhibitors use in patients with heart failure.

Stefania Angela Di Fusco, Antonella Spinelli, Stefano Aquilani, Nunzia Borrelli, Gianmarco Iannopollo, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Furio Colivicchi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Stefania Angela Di FuscoU.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri-ASL Roma 1, PO San Filippo Neri, via Martinotti 20, Rome 00135, Italy.
Antonella SpinelliU.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri-ASL Roma 1, PO San Filippo Neri, via Martinotti 20, Rome 00135, Italy.
Stefano AquilaniU.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri-ASL Roma 1, PO San Filippo Neri, via Martinotti 20, Rome 00135, Italy.
Nunzia BorrelliUnità di Malattie Cardiache Congenite dell'Adulto, AORN dei Colli-Ospedale Monaldi, Via Leonardo Bianchi, 80131 Naples, Italy.
Gianmarco IannopolloUOC Cardiologia, Ospedale Maggiore Carlo Alberto Pizzardi, Largo Bartolo Nigrisoli 2, 40133 Bologna, Italy.
Michele Massimo GuliziaU.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione 'Garibaldi', Via Palermo 636, 95122 Catania, Italy.
Domenico GabrielliU.O.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense 87, 00152 Rome, Italy.
Fabrizio OlivaUnità di Cure Intensive Cardiologiche, Cardiologia 1-Emodinamica, Dipartimento Cardiotoracovascolare 'A. De Gasperis', ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore, 3 - 20162 Milan, Italy.
Furio ColivicchiU.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri-ASL Roma 1, PO San Filippo Neri, via Martinotti 20, Rome 00135, Italy.
Ospedale San Filippo Neri · ITPresidio Ospedaliero · ITAzienda Ospedaliera San Camillo-Forlanini · ITOspedale Garibaldi · ITOspedale Maggiore · ITOspedale Maggiore Carlo Alberto Pizzardi · ITOspedale Monaldi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2-is) have recently been included among the first-line drugs for the treatment of heart failure with reduced ejection fraction. International guidelines recommend SGLT2-i use in association with neuro-hormonal modulators (renin-angiotensin blockers, beta blockers, and aldosterone antagonists). Although SGLT2-is are well tolerated, it is important to know potential side effects and conditions that may lead to an increased risk of adverse events in order to maximize clinical benefits. The aim of this Italian Association of Hospital Cardiologists document is to briefly report clinical evidence that supports SGLT2-i use in patients with heart failure and provide practical indications for clinical implementation.

Indexed as

Heart failurePharmacotherapyPrognosisSodium–glucose cotransporter 2 inhibitors

Identifiers

PMID37213801
PMCPMC10194818
OpenAlexW4377047449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.